A nano-drug delivery system carrying si-RNA, its preparation method, and its application in anti-trastuzumab-resistant breast cancer.

By preparing a nano-drug delivery system carrying siRNA, the problems of trastuzumab resistance in breast cancer and the difficulty of siRNA delivery were solved. This achieved efficient and stable siRNA delivery and ultrasound-controlled sustained release, reversing the drug resistance of breast cancer cells and improving drug utilization.

CN115920068BActive Publication Date: 2026-11-17HANGZHOU BOYI BIOMEDICAL TECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202210797499.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-06
Publication Date
2026-11-17
Estimated Expiration
2042-07-06

AI Technical Summary

Technical Problem

Existing technologies for treating breast cancer, such as trastuzumab, suffer from drug resistance issues. siRNA drugs are prone to degradation, have short half-lives, are difficult to deliver intracellularly, and have poor tumor targeting capabilities, necessitating effective solutions.

Method used

A nanoparticle drug delivery system carrying siRNA was prepared by forming nanoliposomes using a mixture of ethanol and PBS under ultrasonic conditions in a water bath. These nanoliposomes then combined with siRNA, glucose oxidase, and manganese dioxide to form an siRNA nanoparticle drug delivery system, which reverses drug resistance and has an ultrasonically controlled sustained-release function.

Benefits of technology

This technology enables highly efficient and stable siRNA delivery, reverses drug resistance in breast cancer cells, and allows for controlled, sustained drug release via ultrasound. This reduces the frequency of administration, maintains stable drug concentration, improves drug utilization, and lowers the risk of drug resistance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115920068B_ABST
    Figure CN115920068B_ABST
Patent Text Reader

Abstract

This invention discloses a siRNA-carrying nanoparticle drug delivery system, its preparation method, and its application in anti-trastuzumab-resistant breast cancer, belonging to the field of biomedical technology. The method includes: (1) reacting ceramic liposomes, cationic polymers, and perfluorinated carbon in a water bath under ultrasonic conditions using a mixture of ethanol and PBS as a solvent to form nanoliposomes; (2) reacting the obtained nanoliposomes with siRNA, glucose oxidase, and manganese dioxide in a PBS solution to obtain an siRNA nanoparticle drug delivery system. This drug delivery system can efficiently and stably carry siRNA, reversing the drug resistance of trastuzumab-resistant breast cancer cell lines, and has the effects of sustained-release and ultrasound-controlled drug release.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biomedical technology, and in particular to a nano-drug delivery system carrying si-RNA, its preparation method, and its application in anti-trastuzumab-resistant breast cancer. Background Technology

[0002] Trastuzumab is a humanized monoclonal antibody that targets HER2. However, nearly 15% of HER2-positive early breast cancers and 40% of advanced breast cancers develop resistance after treatment with trastuzumab and relapse or distant metastasis within one year.

[0003] As a key effector molecule in RNA therapy (RNA interference technology), siRNA faces significant challenges in drug development: it is easily degraded, has a short half-life, is difficult to deliver intracellularly, and has poor tumor targeting ability. Therefore, given the drug resistance issues of trastuzumab in breast cancer treatment and the limitations of siRNA drugs, there is an urgent need for an effective and feasible method to address the drug resistance problem. Summary of the Invention

[0004] The purpose of this invention is to provide a nano-drug delivery system carrying si-RNA, its preparation method, and its application in anti-trastuzumab-resistant breast cancer, so as to solve the problems existing in the prior art. This nano-drug delivery system can efficiently and stably carry si-RNA, reverse the drug resistance of trastuzumab-resistant breast cancer cell lines, and has the effects of sustained release and ultrasound-controlled drug release.

[0005] To achieve the above objectives, the present invention provides the following solution: This invention provides a method for preparing a nano-drug delivery system carrying siRNA, comprising the following steps: (1) Using a mixture of ethanol and PBS as a solvent, ceramic liposomes, cationic polymers and perfluorinated carbon were reacted under ultrasonic conditions in a water bath to form nanoliposomes; (2) The obtained nanoliposomes, siRNA, glucose oxidase and manganese dioxide were reacted in PBS solution to obtain siRNA nanoparticle drug delivery system.

[0006] Preferably, in step (1), the mass ratio of the ceramic liposome, the cationic polymer, and the perfluorinated carbon is 10:20:1; The volume ratio of ethanol to PBS is 1:10.

[0007] Preferably, in step (1), the water bath ultrasonic conditions are: power 3W, ultrasonic in ice water for 20 min.

[0008] Preferably, in step (2), the mass ratio of the nanoliposomes, the siRNA, the glucose oxidase and the manganese dioxide is 100:1:2:2.

[0009] Preferably, the ceramic liposomes include lipid CFLs, the cationic polymer includes DSPE-PEI, and the perfluorinated carbon is an oxygen-carrying perfluorinated carbon.

[0010] Preferably, the siRNA is a small interfering RNA that inhibits HOTTIP, and its nucleotide sequence is shown in SEQ ID NO:1-SEQ ID NO:2.

[0011] The present invention also provides a drug delivery system for siRNA-carrying nanoparticles prepared by the preparation method described above.

[0012] The present invention also provides an application of the aforementioned siRNA-carrying nanoparticle drug delivery system in the preparation of anti-breast cancer drugs.

[0013] Preferably, the breast cancer includes trastuzumab-resistant breast cancer cell lines.

[0014] Preferably, the application includes the siRNA nanoparticle drug delivery system reversing the resistance of the trastuzumab-resistant breast cancer cell line and providing sustained and ultrasound-controlled release of the drug.

[0015] The present invention discloses the following technical effects: The siRNA-carrying nanoparticle drug delivery system disclosed in this invention can efficiently and stably carry siRNA, solving the problems of easy degradation, short half-life, difficult intracellular delivery, and poor tumor targeting ability of siRNA. At the same time, this drug delivery system solves the problem of trastuzumab resistance by reversing drug resistance in breast cancer cells, and has the advantages of ultrasound-controlled and sustained-release drug delivery, which can reduce the number of dosings, maintain drug concentration, stabilize drug concentration, improve drug utilization, and help reduce or avoid the occurrence of drug resistance. Attached Figure Description

[0016] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0017] Figure 1 To illustrate the difference in drug resistance between two drug-resistant cell lines and the original cell line; A: BT474 / T798M; B: SK-BR-3 / T798M; Figure 2This is a schematic diagram of the chemical structure of CFL; Figure 3 Image showing the morphology of nanoparticles observed using a transmission electron microscope; Figure 4 To determine the particle size of nanoparticles using a particle size potentiometer; Figure 5 To measure the surface potential of nanoparticles using a particle size potentiometer; Figure 6 To detect the sustained-release function of the siRNA-carrying nanodelivery system at 4℃; Figure 7 To detect the sustained-release function of the siRNA-carrying nanodelivery system at 37℃; Figure 8 To investigate the results of reversing trastuzumab resistance in breast cancer cells using the BT474 / T798M cell line; Figure 9 To investigate the results of reversing trastuzumab resistance in breast cancer cells using the drug-resistant cell line SK-BR-3 / T798M; Figure 10 This is a schematic diagram of the synthesis of the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2. Detailed Implementation

[0018] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0019] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0020] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0021] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0022] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0023] Example 1: Construction of two Trastuzumab-resistant strains, BT474 / T798M and SK-BR-3 / T798M. 1. Using the common human breast cancer cell lines BT474 / SK-BR-3 (both purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) as the original cell lines, the cells were cultured in vitro at 37°C and 5% CO2 in RPMI 1640 medium containing 10% FBS until the logarithmic growth phase. Trastuzumab was then added to the medium until the initial effective concentration was 50 nM.

[0024] 2. The effective concentration of Trastuzumab in the culture medium was gradually increased in multiple stages (50 nM, 100 nM, 200 nM and 300 nM respectively). After each increase and maintenance of the concentration, the cells grew stably and were passaged. Finally, Trastuzumab-resistant BT474 / SK-BR-3 cells that could grow stably, be passaged, cryopreserved and revived in a culture medium with an effective concentration of 200 nM Trastuzumab were obtained and named BT474 / T798M and SK-BR-3 / T798M.

[0025] 3. Cell plating density: 5 × 10⁻⁶ 4 Cells were cultured in 96-well plates at concentrations of [number] cells / ml for 24 hours, followed by drug treatment. After another 24 hours, samples were collected, and cell viability was assessed using a CCK-8 assay. The differences in drug resistance between the two resistant cell lines and the original cell line with increasing Trastuzumab concentration were as follows: Figure 1 As shown in the figure. The results showed that, compared with the original cell line, the two drug-resistant cell lines exhibited higher cell viability with increasing drug concentration.

[0026] Example 2 Preparation and characterization of the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2 1. Preparation method of PFC(si-HOTTIP / GOD)@MnO2 A schematic diagram of the synthesis of PFC(si-HOTTIP / GOD)@MnO2 is shown below. Figure 10As shown, the specific preparation method includes the following steps: (1) Synthesis of PFC@CFL-DSPE-PEI nanoliposomes Using water bath sonication, 9.5 μmol CFL and 0.5 μmol DSPE-mPEI (the chemical structure of CFL is shown in Figure 1) were added. Figure 2 As shown, PEI (molecular weight 25000) and 7 μmol PFC (perfluorocarbon) were dissolved in 2 ml of ethanol and 20 ml of PBS, and then thoroughly mixed in an ice bath for 20 minutes using a probe-type sonicator at 50% output power. Uniform nanodroplets of PFC@CFL-DSPE-PEI were obtained by extrusion through a polycarbonate filter (pore size 100 nm) using a liposome extruder.

[0027] (2) si-HOTTIP sequence synthesis Sense (SEQ ID NO:1): 5'-GGGCUUCCUGCAGGAUCCAGACCAA dTdT-3'; Antisense (SEQ ID NO: 2): 3'-dTdT CCCGAAGGACGUCCUAGGUCUGGUU-5'.

[0028] In the above sequence, "d" refers to deoxygenation.

[0029] The above sequence was synthesized by Hanyu Biotech (Beijing, China).

[0030] (3) Preparation of PFC(si-HOTTIP / GOD)@MnO2 Three molecules were transported in PBS solution using electrostatic adsorption of positive and negative charges. The ratio of PFC@CFL-DSPE-PEI to si-HOTTIP, glucose oxidase (GOD), and MnO2 (nanoparticle size: 24 nm) was adjusted to simultaneously ensure high loading and nanoparticle stability. The specific procedures are as follows: Take 10 mg of nanoliposomes, disperse them in 30 ml of PBS solution, stir well, add 100 μg of si-HOTTIP, 200 μg of glucose oxidase (GOD) and 200 μg of MnO2, add PBS solution to make up the total volume to 40 ml, stir overnight at 4°C in the dark.

[0031] 2. Characterization of PFC(si-HOTTIP / GOD)@MnO2 (1) The morphology of the nanoparticles was observed using a transmission electron microscope (TEM; JEM-1400Plus, JEOL, Japan). The results are as follows: Figure 3As shown, the nanoparticles have a spherical structure and are individually dispersed without adhesion.

[0032] (2) The particle size of the nanoparticles was determined using a particle size potentiometer (Zetasizer Nano ZSP, Malvern, UK). The results are as follows: Figure 4 As shown, the diameter of the nanoparticles is 85 nm (measurement angle is 173°, measurement temperature is 25℃).

[0033] (3) The surface potential of the nanoparticles was measured using a particle size potentiometer (Zetasizer Nano ZSP, Malvern, UK). The results are as follows: Figure 5 As shown, the surface potential of the nanoparticles is -3.88mV.

[0034] Example 3 Functional validation of the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2 To detect the sustained-release function of the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2, it was tested at 4℃ for 48 h under different pH and US conditions (US being ultrasonic treatment at 20 kHz and 0.15 W / cm²). 2 The sustained-release effect of si-HOTTIP. We set up grouping: (1) 4℃, pH 6.5, US; (2) 4℃, pH 6.5; (3) 4℃, pH 7.4.

[0035] The release of si-HOTTIP was detected using a NanoDrop spectrophotometer.

[0036] The results are as follows Figure 6 As shown, at 4℃, pH 6.5, 20kHz, and 0.15W / cm², 2 Under ultrasonic treatment, the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2 exhibits better si-HOTTIP sustained-release effect.

[0037] Example 4 Functional validation of the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2 The difference from Example 3 is that 4°C is replaced with 37°C, while all other steps remain the same.

[0038] The results are as follows Figure 7 As shown, at 37℃, pH 6.5, 20kHz, and 0.15W / cm², 2 Under ultrasonic treatment, the nano-drug delivery system PFC(si-HOTTIP / GOD)@MnO2 exhibits better si-HOTTIP sustained-release effect.

[0039] Example 5: Detection of the effect of PFC(si-HOTTIP / GOD)@MnO2 on reversing trastuzumab resistance in breast cancer Group as shown below: 1) Blank control group; 2) si-HOTTIP interference group; 3) PFC(si-HOTTIP / GOD)@MnO2 group; 4) PFC (si-HOTTIP / GOD) @MnO2+pH6.5 treatment group; 5) PFC(si-HOTTIP / GOD)@MnO2+pH6.5+US treatment group.

[0040] 50 nM trastuzumab was used to coat the above-mentioned drug-resistant cell lines (SK-BR-3 / T798M, plated at a density of 5 × 10⁶ cells / year). 4 After incubating with the cells (cells / ml) for 24 h, the cells were collected, washed three times with complete culture medium, and cell viability was detected using the CCK-8 assay kit.

[0041] like Figure 8 As shown, the results indicate that nanoparticles can significantly reduce the viability of trastuzumab-treated resistant cell line SK-BR-3 / T798M. This means that the resistance of trastuzumab to SK-BR-3 / T798M cell line can be reversed after treatment with nanomedicine, which also verifies the advantages of in vitro ultrasound-triggered controllable nanotechnology.

[0042] Example 6: Detection of the effect of PFC(si-HOTTIP / GOD)@MnO2 on reversing trastuzumab resistance in breast cancer The difference from Example 5 is that the drug-resistant cell line SK-BR-3 / T798M is replaced with BT474 / T798M, while all other steps are the same.

[0043] The results are as follows Figure 9 As shown, the results indicate that nanoparticles can significantly reduce the viability of trastuzumab-treated resistant cell line BT474 / T798M. This means that the resistance of resistant cell line BT474 / T798M to trastuzumab can be reversed after treatment with nanomedicine, which also verifies the advantages of in vitro ultrasound-triggered controllable nanotechnology.

[0044] The embodiments described above are merely preferred embodiments of the present invention and are not intended to limit the scope of the present invention. Various modifications and improvements made by those skilled in the art to the technical solutions of the present invention without departing from the spirit of the present invention should fall within the protection scope defined by the claims of the present invention.

Claims

1. A method for preparing a nanodelivery system loaded with siRNA, characterized in that, Includes the following steps: (1) Using a mixture of ethanol and PBS as a solvent, ceramic liposomes, cationic polymers and perfluorinated carbon were reacted under ultrasonic conditions in a water bath to form nanoliposomes; (2) The obtained nanoliposomes, siRNA, glucose oxidase and manganese dioxide nanoparticles were reacted in PBS solution to obtain a nano-drug delivery system carrying siRNA. The ceramic liposome is a lipid CFL, and the cationic polymer is DSPE-PEI; the chemical structural formula of the CFL is: ; The siRNA is a small interfering RNA that inhibits HOTTIP, and its nucleotide sequence is shown in SEQ ID NO:1-SEQ ID NO:

2.

2. The production method according to claim 1, wherein In step (1), the mass ratio of the ceramic liposomes, cationic polymers and perfluorinated carbon is 10:20:1; The volume ratio of ethanol to PBS is 1:

10.

3. The production method according to claim 1, wherein In step (1), the water bath ultrasonic conditions are: power 3W, ultrasonic in ice water for 20 min.

4. The production method according to claim 1, wherein In step (2), the mass ratio of the nanoliposomes, the siRNA, the glucose oxidase and the manganese dioxide nanoparticles is 100:1:2:

2.

5. The production method according to claim 1, wherein The perfluorinated carbon is an oxygen-carrying perfluorinated carbon.

6. The siRNA-carrying nanodelivery system prepared by the preparation method described in claim 1.

7. The application of the siRNA-carrying nanodelivery system as described in claim 6 in the preparation of anti-breast cancer drugs.

8. Use according to claim 7, wherein the compound is ###0002### The breast cancers mentioned include trastuzumab-resistant breast cancer cell lines.

Citation Information

Patent Citations

  • Preparation method of siRNA and chemotherapeutic-coloaded cationic lipid-meso-porous silicon composite nanocarrier

    CN108938595A

  • Nano therapeutic agent and preparation method and application thereof

    CN110403916A

  • Preparation method and application of glucose-oxidase-modified mesoporous manganese dioxide composition

    CN110743012A

  • Perfluocarbon silicon plastid as well as preparation method and application thereof

    CN112546062A

  • Nanoparticle with synergistic enhancement effect of removing active oxygen and resisting inflammation

    CN113244409A